Frontiers in medicine · 2025
The value of NLR, PLR, PCT, and D-D levels in assessing the severity of hyperlipidemic acute pancreatitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Lili, Xiao Jinliang, Fan Lijuan
Аннотация
BACKGROUND: The incidence of hyperlipidemic acute pancreatitis (HLAP) has been increasing yearly, presenting a younger demographic and high mortality rates. Early assessment of severity is essential for improving treatment strategies and outcomes. Various serum biomarkers, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), have shown prognostic value in inflammatory conditions.
OBJECTIVE: This study aims to evaluate NLR, PLR, procalcitonin (PCT), and D-dimer (D-D) as biomarkers in assessing HLAP severity, identify independent predictors factors for moderate-to-severe HLAP, and provide evidence for tailored therapeutic interventions.
METHODS: A retrospective analysis was conducted on 145 HLAP patients admitted between mid-2021 and mid-2023 at Jining No. 1 People's Hospital. Patients were categorized into mild HLAP and moderate-to-severe HLAP groups based on severity. Clinical and biochemical data were analyzed using SPSS 26.0, and the diagnostic efficacy of NLR, PLR, PCT, and D-D was evaluated via Receiver Operating Characteristic (ROC) curve.
RESULTS: Elevated levels of NLR, PLR, PCT, and D-D were identified as independent predictors for moderate-to-severe HLAP. The combined ROC curve for these biomarkers yielded an area under the curve (AUC) of 0.898 (95% CI: 0.841-0.956), with sensitivity and specificity of 0.818 and 0.892, respectively, outperforming individual biomarkers.
CONCLUSIONS: The combined assessment of NLR, PLR, PCT, and D-D is a simple, efficient, and cost-effective method for early HLAP severity evaluation. Further large-scale studies are warranted to validate these findings.
OBJECTIVE: This study aims to evaluate NLR, PLR, procalcitonin (PCT), and D-dimer (D-D) as biomarkers in assessing HLAP severity, identify independent predictors factors for moderate-to-severe HLAP, and provide evidence for tailored therapeutic interventions.
METHODS: A retrospective analysis was conducted on 145 HLAP patients admitted between mid-2021 and mid-2023 at Jining No. 1 People's Hospital. Patients were categorized into mild HLAP and moderate-to-severe HLAP groups based on severity. Clinical and biochemical data were analyzed using SPSS 26.0, and the diagnostic efficacy of NLR, PLR, PCT, and D-D was evaluated via Receiver Operating Characteristic (ROC) curve.
RESULTS: Elevated levels of NLR, PLR, PCT, and D-D were identified as independent predictors for moderate-to-severe HLAP. The combined ROC curve for these biomarkers yielded an area under the curve (AUC) of 0.898 (95% CI: 0.841-0.956), with sensitivity and specificity of 0.818 and 0.892, respectively, outperforming individual biomarkers.
CONCLUSIONS: The combined assessment of NLR, PLR, PCT, and D-D is a simple, efficient, and cost-effective method for early HLAP severity evaluation. Further large-scale studies are warranted to validate these findings.